Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study-Reference-Cited by-同舟云学术

Vericiguat in Combination with Short‐Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study

Published:2022-03-28 Issue:6 Volume:111 Page:1239-1247
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Boettcher Michael¹,Düngen Hans‐Dirk²,Donath Frank³,Mikus Gerd⁴,Werner Nikos⁵,Thuermann Petra A.⁶,Karakas Mahir⁷,Besche Nina⁸,Koch Tanja⁹,Gurniak Matthias⁹,Becker Corina¹

Affiliation:

1. Clinical Pharmacology Bayer AG Wuppertal Germany

2. Department of Internal Medicine, Cardiology Charité – Universitaetsmedizin Berlin Berlin Germany

3. SocraTec Research & Development GmbH Erfurt Germany

4. Department of Clinical Pharmacology and Pharmacoepidemiology University Hospital Heidelberg Heidelberg Germany

5. Heart Center, Department of Medicine II University Hospital Bonn Bonn Germany

6. Philipp Klee‐Institute of Clinical Pharmacology, Helios Klinikum Wuppertal Wuppertal Germany

7. Department of Cardiology University Heart & Vascular Center Hamburg Hamburg Germany

8. Chrestos Concept GmbH & Co. KG Essen Germany

9. Translational Studies Operations, Bayer AG Wuppertal Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2574

Reference23 articles.

1. The annual global economic burden of heart failure

2. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction

3. Heart Failure and Comorbidities

4. Heart Failure in the Twenty-First Century: Is it a Coronary Artery Disease or Hypertension Problem?

5. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial;Frontiers in Pharmacology;2024-06-12

2. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat;Clinical Pharmacokinetics;2024-06

3. New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration;Rational Pharmacotherapy in Cardiology;2024-02-06

4. Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases;Frontiers in Pharmacology;2023-12-20

5. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2023-11-23